Ozempic (semaglutide) Developer: Novo Nordisk Modality: Peptide PDUFA Date: January 2025 Indication/Description: Metabolic, Renal / A new indication for once-weekly subcutaneous semaglutide to treat adults with type 2 diabetes and chronic kidney disease (CKD), including delaying CKD progression and reducing the risk of kidney and cardiovascular death
Branded Ozempic and Wegovy in Thailand Branded Ozempic (semaglutide for diabetes) and Wegovy (semaglutide for weight management) are available at some clinics and pharmacies in Thailand
AHK-Cu also delivers copper, but its delivery efficiency to the specific cells that express 5-alpha reductase has not been directly compared
The underlying premise is that adiposity drives multiple disease states, and treating the metabolic root can improve outcomes across all of them
More data from the CDC shows that a staggering 38.4 million Americans are currently living with type 2 diabetes, which accounts for approximately 90 to 95 percent of all cases
Zepbound, with the active ingredient tirzepatide, represents a groundbreaking advancement in weight loss medication
